A vs. BIO: Agilent vs. Bio-Rad Laboratories Stock Comparison

November 11, 2026

How do Agilent (A) and Bio-Rad Laboratories (BIO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and Bio-Rad Laboratories (BIO) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Agilent (A) and Bio-Rad Laboratories (BIO)
Profile Item	A	BIO
Name	AgileThought, Inc. Class A Common Stock	Bio-Rad Laboratories Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
GICS Sub-Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
Market Capitalization	49.28 billion USD	10.26 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	November 18, 1999	February 27, 1980
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

BIO

GSPC

Agilent (A) vs. Bio-Rad Laboratories (BIO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Agilent (A) and Bio-Rad Laboratories (BIO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Agilent (A) and Bio-Rad Laboratories (BIO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and Bio-Rad Laboratories (BIO)
Metric	A	BIO
Total Return (1Y)	22.92%	28.31%
Total Return (3Y, Annualized)	19.33%	8.52%
Total Return (5Y, Annualized)	3.03%	-11.74%

Risk Profile

Drawdown History

BIO

GSPC

Agilent (A) vs. Bio-Rad Laboratories (BIO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Agilent (A) and Bio-Rad Laboratories (BIO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and Bio-Rad Laboratories (BIO)
Metric	A	BIO
Volatility (1Y, Annualized)	33.10%	36.50%
Beta (5Y)	1.22	1.03
Max Drawdown (5Y)	-38.09%	-72.24%
Avg. Volume (3M)	2.25M	250.78K

Risk-Adjusted Performance

Risk-Return Positioning

A and BIO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and Bio-Rad Laboratories (BIO)
Metric	A	BIO
Sharpe Ratio (1Y)	0.56	0.66
Sortino Ratio (1Y)	0.96	0.98

Profitability

ROE (TTM)

Both Agilent (A) at 20.97% and Bio-Rad Laboratories (BIO) at 14.27% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max: 109.18%
A: 20.97%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max: 109.18%
BIO: 14.27%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Agilent (A) vs. Bio-Rad Laboratories (BIO): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Agilent (A) at 19.53% and Bio-Rad Laboratories (BIO) at 39.45% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A: 19.53%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO: 39.45%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Agilent (A) vs. Bio-Rad Laboratories (BIO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Agilent (A) at 25.56% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max: 83.12%
A: 25.56%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.82%

Max: 83.12%
Q3: 14.77%
BIO: 11.82%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Agilent (A) vs. Bio-Rad Laboratories (BIO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and Bio-Rad Laboratories (BIO)
Metric	A	BIO
ROE (TTM)	20.97%	14.27%
ROA (TTM)	8.63%	1.50%
Net Margin (TTM)	19.53%	39.45%
Operating Margin (TTM)	25.56%	11.82%
Gross Margin (TTM)	53.65%	52.19%

Growth

Revenue Growth

Both Agilent (A) at 6.73% and Bio-Rad Laboratories (BIO) at 0.65% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Agilent (A) vs. Bio-Rad Laboratories (BIO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Agilent (A) reports EPS growth of 3.16%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.

Agilent (A) vs. Bio-Rad Laboratories (BIO): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and Bio-Rad Laboratories (BIO)
Metric	A	BIO
Revenue Growth (YoY)	6.73%	0.65%
Revenue Growth (3Y CAGR)	0.48%	-2.68%
EPS Growth (YoY)	3.16%	--
EPS Growth (3Y CAGR)	3.02%	--

Financial Strength

Current Ratio (MRQ)

Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while Agilent (A) at 2.05 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for A.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
A: 2.05
Min: 0.10

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max: 25.13
Q3: 12.13
Median: 5.52
BIO: 3.18
Q1: 2.47
Min: 0.10

Agilent (A) vs. Bio-Rad Laboratories (BIO): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Agilent (A) at 0.56 and Bio-Rad Laboratories (BIO) at 0.18 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max: 1.42
Q3: 0.65
A: 0.56
Median: 0.15
Q1: 0.02
Min: 0.00

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max: 1.42
Q3: 0.65
BIO: 0.18
Median: 0.15
Q1: 0.02
Min: 0.00

Agilent (A) vs. Bio-Rad Laboratories (BIO): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and Bio-Rad Laboratories (BIO)
Metric	A	BIO
Current Ratio (MRQ)	2.05	3.18
Debt / Equity (MRQ)	0.56	0.18
Net Debt / EBITDA	1.15	-0.73

Dividends

Dividend Yield (TTM)

Bio-Rad Laboratories (BIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A: 0.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. Bio-Rad Laboratories (BIO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A: 19.98%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. Bio-Rad Laboratories (BIO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and Bio-Rad Laboratories (BIO)
Metric	A	BIO
Dividend Yield (TTM)	0.59%	0.00%
Dividend Payout Ratio (TTM)	19.98%	0.00%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Agilent (A) at 34.47 is closer to its industry’s usual earnings multiple — a discount for BIO, though growth and earnings durability still matter.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max: 85.34
Q3: 43.46
A: 34.47
Median: 26.69
Q1: 13.30
Min: 0.07

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.14

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
BIO: 10.14
Min: 0.07

Agilent (A) vs. Bio-Rad Laboratories (BIO): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Agilent (A) at 6.68 and Bio-Rad Laboratories (BIO) at 3.96 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max: 58.18
Q3: 25.77
Median: 7.30
A: 6.68
Q1: 3.01
Min: 0.01

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.96

Max: 58.18
Q3: 25.77
Median: 7.30
BIO: 3.96
Q1: 3.01
Min: 0.01

Agilent (A) vs. Bio-Rad Laboratories (BIO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO) at 1.35 looks cheap against book in the lower P/B ratio quartile, while Agilent (A) at 6.69 carries a premium in the upper quartile — a clear price-to-book gap.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max: 13.53
A: 6.69
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.35

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
BIO: 1.35
Min: -5.59

Agilent (A) vs. Bio-Rad Laboratories (BIO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and Bio-Rad Laboratories (BIO)
Metric	A	BIO
P/E Ratio (TTM)	34.47	10.14
P/S Ratio (TTM)	6.68	3.96
P/B Ratio (MRQ)	6.69	1.35
Free Cash Flow Yield (TTM)	2.15%	2.65%